The economic burden of biologic disease-modifying antirheumatic drugs in rheumatoid arthritis patients in the United States.
Qian DingDane L ShiltzDana HossamiAlison M KoniecznyPublished in: Expert review of pharmacoeconomics & outcomes research (2022)
RA patients receiving TNF alpha biologics experienced significantly higher total medical and out-of-pocket expenditures; however, they experienced fewer or no occurrences of high-cost drivers of healthcare utilization compared to patients receiving conventional DMARDs.